Skip to main content

CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study

Clinical and Translational Oncology volume 21, pages 167–177 (2019)Cite this article

Abstract

Purpose

To assess the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) in liver cancer patients with different times of previous conventional transarterial chemoembolization (cTACE) treatments.

Methods

367 liver cancer patients about to receive DEB-TACE treatment were enrolled in this prospective cohort study. All patients were divided into no previous cTACE group (NPC group), 1–2 times previous cTACE group (PC group) and triple or above previous cTACE group (TPC group) according to the times of previous cTACE treatments.

Results

There was no difference in complete response (CR) (P = 0.671) and objective response rate (ORR) (P = 0.062) among three groups. Additionally, no difference in overall survival (OS) among groups (P = 0.899) was found. As to liver function, most liver function indexes were deteriorative at 1 week after DEB-TACE operation, but returned to baseline at 1–3 months after DEB-TACE operation in all three groups, while percentage of abnormal total bile acid (TBA) patients was higher in TPC group than NPC and PC groups at 1–3 month post-DEB-TACE (P = 0.018). As for safety profiles, the incidence of pain during DEB-TACE operation was lower in TPC group compared to NPC and PC groups (P = 0.005), while no difference of other adverse events was found during and 1 month post-DEB-TACE treatment among three groups.

Conclusion

DEB-TACE treatment was equally efficient and tolerated in liver cancer patients with different times of previous cTACE treatments.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

References

  1. Recio-Boiles A, Babiker HM. Cancer, Liver. StatPearls. Treasure Island (FL)2017.

  2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. https://doi.org/10.3322/caac.21262.

    Article  Google Scholar 

  3. Chen P, Yuan P, Chen B, Sun J, Shen H, Qian Y. Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41(1):75–85. https://doi.org/10.1016/j.clinre.2016.05.013.

    Article  CAS  PubMed  Google Scholar 

  4. European Association For The Study Of The. L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43. https://doi.org/10.1016/j.jhep.2011.12.001.

    Article  Google Scholar 

  5. Bruix J, Sherman M. American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2. https://doi.org/10.1002/hep.24199.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Ludwig JM, Zhang D, Xing M, Kim HS. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90Y-radioembolization for hepatocellular carcinoma. Eur Radiol. 2017;27(5):2031–41. https://doi.org/10.1007/s00330-016-4548-3.

    Article  PubMed  Google Scholar 

  7. Ni JY, Xu LF, Wang WD, Sun HL, Chen YT. Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: a meta-analysis. World J Gastroenterol. 2014;20(45):17206–17. https://doi.org/10.3748/wjg.v20.i45.17206.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Xie ZB, Wang XB, Peng YC, Zhu SL, Ma L, Xiang BD, et al. Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. Hepatol Res. 2015;45(2):190–200. https://doi.org/10.1111/hepr.12450.

    Article  CAS  PubMed  Google Scholar 

  9. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. https://doi.org/10.1055/s-0030-1247132.

    Article  CAS  Google Scholar 

  10. Terzi E, Golfieri R, Piscaglia F, Galassi M, Dazzi A, Leoni S, et al. Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”. J Hepatol. 2012;57(6):1258–67. https://doi.org/10.1016/j.jhep.2012.07.025.

    Article  CAS  PubMed  Google Scholar 

  11. Sangro B, D’Avola D, Inarrairaegui M, Prieto J. Transarterial therapies for hepatocellular carcinoma. Expert Opin Pharmacother. 2011;12(7):1057–73. https://doi.org/10.1517/14656566.2011.545346.

    Article  CAS  PubMed  Google Scholar 

  12. Kudo M, Matsui O, Izumi N, Kadoya M, Okusaka T, Miyayama S, et al. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology. 2014;87(Suppl 1):22–31. https://doi.org/10.1159/000368142.

    Article  CAS  PubMed  Google Scholar 

  13. Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis. Dig Liver Dis. 2016;48(6):571–7. https://doi.org/10.1016/j.dld.2016.02.005.

    Article  CAS  Google Scholar 

  14. Song MJ, Chun HJ, Song DS, Kim HY, Yoo SH, Park CH, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol. 2012;57(6):1244–50. https://doi.org/10.1016/j.jhep.2012.07.017.

    Article  CAS  PubMed  Google Scholar 

  15. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33(1):41–52. https://doi.org/10.1007/s00270-009-9711-7.

    Article  Google Scholar 

  16. Song DS, Choi JY, Yoo SH, Kim HY, Song MJ, Bae SH, et al. DC bead transarterial chemoembolization is effective in hepatocellular carcinoma refractory to conventional transarteral chemoembolization: a pilot study. Gut Liver. 2013;7(1):89–95. https://doi.org/10.5009/gnl.2013.7.1.89.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Huang K, Zhou Q, Wang R, Cheng D, Ma Y. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29(5):920–5. https://doi.org/10.1111/jgh.12439.

    Article  CAS  PubMed  Google Scholar 

  18. Zou JH, Zhang L, Ren ZG, Ye SL. Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis. J Dig Dis. 2016;17(8):510–7. https://doi.org/10.1111/1751-2980.12380.

    Article  CAS  PubMed  Google Scholar 

  19. Jang JH, Lee JW, Hong JT, Jin YJ. Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy. J Hepatocell Carcinoma. 2015;2:123–9. https://doi.org/10.2147/JHC.S44380.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol. 2009;27:147–63. https://doi.org/10.1146/annurev.immunol.021908.132629.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Nature Science Foundation of China (81371658) and Zhejiang Provincial Natural Science Foundation of China (LZ18H180001).

Funding

This work was supported by the National Nature Science Foundation of China (81371658) and Zhejiang Provincial Natural Science Foundation of China (LZ18H180001).

Author information

Author notes

  1. Xin Zhang and Jian Zhou contributed equally to this work.

Affiliations

  1. Interventional Radiology Department, The First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310006, China

    X. Zhang, Z.-Y. Peng & S.-H. Ying

  2. Department of Radiology, Hangzhou Cancer Hospital, No. 34 Yan Guan lane, Hangzhou, China

    J. Zhou

  3. Department of Liver Oncology, Ningbo No. 2 Hospital, No. 41 Xibei Road, Ningbo, 315010, China

    D.-D. Zhu & L. Li

  4. Department of Hepatobiliary Surgery, Ningbo Medical Center Lihuili Easter Hospital, No. 1111 Jiangnan Road, Ningbo, 315000, China

    J. Huang

  5. Department of Radiology, Beilun District People’s Hospital of Ningbo, No. 1288 Lushang East Road, Ningbo, 315826, China

    T.-F. Li

  6. Department of Intervention, Ruian People’s Hospital, The Third Affiliated Hospital of Wenzhou Medical University, No. 108 Wansong Road, Ruian, 325200, China

    C.-S. Shi

  7. Department of Radiology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Hospital of TCM, No. 54 Youdian Road, Hangzhou, 310006, China

    Z.-C. Sun

  8. Department of Radiology, Xixi Hospital of Hangzhou, Hangzhou 6th People’s Hospital, Hengbu Street 2, Hangzhou, 310023, China

    Q.-M. Hou

  9. Department of Intervention, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, No. 158 Shangtang Road, Hangzhou, 310000, China

    W.-Q. Yu & T.-Y. Hu

  10. Department of Radiology, Lishui Central Hospital, Lishui Hospital of Zhejiang University, The Fifth Affiliated Hospital of Wenzhou Medical University, No. 289 Kuocang Road, Lishui, 323000, China

    J.-S. Ji

  11. Department of Intervention, Jiaxing Second Hospital, No. 1518 Huangcheng North Road, Jiaxing, 314000, China

    W.-J. Gu

  12. Division of Hepatobiliary and Pancreatic Surgery, Hepatobiliary and Pancreatic Interventional Treatment Center, The First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310006, China

    J.-H. Sun & G.-H. Zhou

  13. Interventional Center, Xinchang People’s Hospital, No. 117 Gushan Road, Xinchang, 312500, China

    X.-X Xie

  14. Department of Intervention, Jinhua Municipal Central Hospital, Jinhua Hospital of Zhejiang University, No. 365 Renmin East Road, Jinhua, 321000, China

    X.-H. Guo

  15. Department of Radiology, Shulan (Hangzhou) Hospital, No. 848 Dongxin Road, Hangzhou, 310026, China

    G.-H. Cao

  16. Department of Vascular and Interventional Radiology, The Affiliated Hospital of Medical School of Ningbo University, No. 247 Renmin Road, Ningbo, 315020, China

    Z.-H. Yu

  17. Division of Digestive Endoscopy, Yueqing City People’s Hospital, No. 338 Qingyuan Road, Yueqing, 325600, China

    H.-H. Xu

  18. Department of Hepatobiliary Surgery, Quzhou People’s Hospital, No. 2 Zhongloudi, Quzhou, 324000, China

    J. Fang

  19. Department of Intervention, The First Provincial Wenzhou Hospital of Zhejiang, The First Affiliated Hospital of Wenzhou Medical University, No. 2 Fuxue Lane, Wenzhou, 325099, China

    W.-H. Hu

  20. Department of Radiology, Taizhou Hospital of Zhejiang Province, No. 150 Ximen Street, Linhai, 317000, China

    W.-B. Ji

  21. Department of Intervention, Jiaxing First Hospital, No. 1882 Zhonghuan South Road, Jiaxing, 314001, China

    J. Han

  22. Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No. 3 Qingchun East Road, Hangzhou, 310016, China

    X. Wu & H.-J. Hu

  23. Department of Intervention, Zhejiang Cancer Hospital, No. 1 Banshan East Road, Hangzhou, 310022, China

    J.-P. Zheng, J. Luo, Y.-T. Chen & G.-L. Shao

  24. Department of Intervention, Dongyang People’s Hospital, No. 60 Wuning West Road, Dongyang, 322100, China

    H.-J. Du

Authors
  1. X. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D.-D. Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J.-H. Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T.-F. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C.-S. Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Z.-C. Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Q.-M. Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Z.-Y. Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. W.-Q. Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J.-S. Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. W.-J. Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. G.-H. Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. X.-X Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. X.-H. Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. G.-H. Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Z.-H. Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. H.-H. Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. J. Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. S.-H. Ying
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. W.-H. Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. W.-B. Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. J. Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. X. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. J.-P. Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. J. Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. Y.-T. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. T.-Y. Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  30. L. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  31. H.-J. Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  32. H.-J. Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  33. G.-L. Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to H.-J. Du or G.-L. Shao.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in this study were in accordance with the ethical standards of the institutional ethics committee and with the 1964 Helsinki declaration and its later amendments.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 165 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhang, X., Zhou, J., Zhu, DD. et al. CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study. Clin Transl Oncol 21, 167–177 (2019). https://doi.org/10.1007/s12094-018-1902-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-018-1902-8

Keywords

  • Drug-eluting beads transarterial chemoembolization (DEB-TACE)
  • Efficacy
  • Safety
  • Previous cTACE treatment
  • Liver cancer